Medtronic ASPIREs to artificial pancreas – trial results bring it a step closer
This article was originally published in Clinica
Executive Summary
Medtronic's artificial pancreas has edged closer to becoming a reality after the company reported positive results from the first stage of its ASPIRE study, conducted in a clinical setting. ASPIRE (Automation to Simulate Pancreatic Insulin Response) is testing Medtronic's MiniMed Paradigm Veo insulin pump which features low glucose suspend (LGS) technology, a critical component in a successful artificial pancreas system.